Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

4D Molecular Therapeutics And MedImmune Collaborate To Design, Develop, And Commercialize AAV Gene Therapy

By MedImmune | July 11, 2018

MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics (4DMT), a company focusing on Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease, utilizing 4DMT’s novel discovery platform to generate optimized AAV vectors.

AAV vectors are a leading delivery vehicle for transporting genes to accessible tissues in the body for in-vivo expression and therapeutic application. They target both dividing and nondividing cells without integrating genetic material into the host genome. The genetic material transferred by AAV vectors into cells is the blueprint for the production of a protein whose function targets pathological processes contributing to diseases.

The collaboration will leverage 4DMT’s expertise in vector discovery and engineering, optimization and process development. MedImmune will conduct product development beginning from early clinical stages, drawing on the company’s extensive expertise in respiratory science.

Roland Kolbeck, vice president, research & development respiratory, inflammation and autoimmunity at MedImmune, said, “Rapid advances in AAV therapy make this a promising tool to advance innovation in chronic lung disease, particularly in areas of high unmet need. This collaboration strategically pairs 4DMT’s expertise in AAV with MedImmune’s leadership in respiratory science, focused on early intervention and disease modification.”

David Kirn MD, CEO and co-founder of 4DMT, added, “This exciting collaboration may open the door to significant advancements in treatment for respiratory patients. Our progress in customized AAV vectors enables us to unlock the potential of gene therapy and, with MedImmune’s expertise in protein engineering, we will continue to push boundaries in proprietary gene delivery to tissues and cells.”

(Source: MedImmune)


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE